Vadastuximab Talirine (33a) plus a Hypomethylating Agent (HMA): A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)-MedSci.cn

Vadastuximab Talirine (33a) plus a Hypomethylating Agent (HMA): A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)

Walter, RB; Fathi, AT

ANNALS OF HEMATOLOGY, 2017; 96 ( ): S85

科室
- - 订阅+
  - 更多科室
工具
服务